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ABSTRACT
Purpose Pre-licensure studies have limited ability to detect rare adverse events (AEs) to vaccines, requiring timely post-licensure studies.
With the increasing availability of electronic health records (EHR) near real-time vaccine safety surveillance using these data has emerged as
an option. We reviewed methods currently used to inform development of similar systems for countries considering their introduction.
Methods Medline, EMBASE and Web of Science were searched, with additional searches of conference abstract books. Questionnaires
were sent to organizations worldwide to ascertain unpublished studies. Eligible studies used EHR and regularly assessed pre-speciﬁed AE
to vaccine(s). Key features of studies were compared descriptively.
Results From 2779 studies, 31 were included from the USA (23), UK (6), and Taiwan and New Zealand (1 each). These were
published/conducted between May 2005 and April 2015. Thirty-eight different vaccines were studied, focusing mainly on inﬂuenza
(47.4%), especially 2009 H1N1 vaccines. Forty-six analytic approaches were used, reﬂecting frequency of EHR updates and the AE studied.
Poisson-based maximized sequential probability ratio test was the most common (43.5%), followed by its binomial (23.9%) and conditional
versions (10.9%). Thirty-seven of 49 analyses (75.5%) mentioned control for confounding, using an adjusted expected rate (51.4% of those
adjusting), stratiﬁcation (16.2%) or a combination of a self-controlled design and stratiﬁcation (13.5%). Guillain-Barré syndrome (11.9%),
meningitis/encephalitis/myelitis (11.9%) and seizures (10.8%) were studied most often.
Conclusions Near real-time vaccine safety surveillance using EHR has developed over the past decade but is not yet widely used. As more
countries have access to EHR, it will be important that appropriate methods are selected, considering the data available and AE of interest.
© 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
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INTRODUCTION
Vaccines are considered to be one of the most cost-
effective interventions in public health.1,2 As with
other drugs, vaccines are not totally safe,3 but safety
requirements are particularly high as vaccines are
given to healthy individuals, most often children.4
All vaccines go through extensive safety assessment
before licensure; however, pre-licensure studies have
limited ability to detect rare adverse events (AEs) to
vaccines (with frequency <1/10000-1/100000)5, AE
occurring among speciﬁc sub-populations who were
not included in clinical trials, and long-term AE.6 To
overcome these limitations, timely post-licensure stud-
ies are required. These can be broadly divided into
passive (spontaneous reports) and active studies and
should be followed by conﬁrmatory epidemiologic
studies. While spontaneous reporting of AE is widely
implemented worldwide as a simple and low-cost
method, useful to detect new, unanticipated AE, it
has limitations.2 These include difﬁculties in denomi-
nator calculation, potential reporting biases (e.g. over-
reporting of potential AE receiving extensive media
coverage) and incomplete reporting. In contrast, active
surveillance tries to identify all those experiencing
(or at least seeking medical attention for) a potential
AE to vaccines. This approach includes analyses
of large population datasets (using electronic health
records (EHR)), targeted hospital-based surveillance
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(where trained health workers daily seek potential
cases of conditions of interest) and recruitment of vac-
cinated cohorts for detection of AE (using face-to-face
interviews, phone interviews, short-message services
or web-based tools).7,8 With the increased availability
of large population datasets, near real-time vaccine
safety surveillance (NRTVSS) has emerged as an
option.9
Near real-time vaccine safety surveillance, also
known as rapid cycle analysis, involves regular inter-
rogation of EHR to investigate pre-speciﬁed AE to
vaccines.2 By testing these AE on a regular basis after
introduction of a new vaccine, these methods ensure a
timely detection of possible safety problems.10 When a
signal is detected by this approach, it needs to be fur-
ther analysed, including a signal reﬁnement stage and
eventual conﬁrmatory analyses. These steps should
be predetermined and will lead to the decision of
whether to validate or invalidate the signal. NRTVSS
is thus part of a systematic approach to signal detec-
tion, with a dual role of signalling possible AE to vac-
cines and reassuring authorities and populations that
events are being monitored.11 For a given vaccine,
NRTVSS only considers a small number of suspected
AE (e.g. 5 to 10); complementary information is pro-
vided by existing methods such as spontaneous
reports.12
The growing use of NRTVSS methods, along with
the increasing availability of EHR, highlights the need
to review studies using this approach. Such a review
can provide crucial information on the development
of systems for vaccine safety surveillance for countries
considering their introduction.
OBJECTIVE
The aim of this study was to carry out a systematic re-
view of published and unpublished data on the
methods used for NRTVSS using EHR.
METHODS
Studies were included in the review if they (i) used
routinely collected health data (at least for the ex-
pected number of events); (ii) studied pre-speciﬁed
outcome(s) to assess the safety of one or more vac-
cines; and (iii) regularly tested the outcomes.
Studies (i) including only information based on
spontaneous reporting systems, (ii) aimed at testing
hypothesis/conﬁrming previously generated/suspected
signals or (iii) aimed at developing new methods for
NRTVSS (unless a speciﬁc application of the new
method was given) were excluded. No limits were im-
posed in terms of language or year.
Medline and EMBASE were searched for studies
published until 6 January 2015, using a combination
of thesaurus and free-text terms (search strategy is pro-
vided in Supporting Information Appendix A). Titles
and abstracts were reviewed to determine eligibility
status, followed by the full text for those considered
potentially eligible. References from the papers col-
lected were also reviewed. Reviews of the topic were
selected for reference mining. A.L. was responsible
for evaluating eligibility of the identiﬁed studies. To
ensure quality, eligibility of a random sample of 10%
of the results was evaluated by S.T. and N.A. When
eligibility was unclear, the study was discussed among
the authors until a consensus was reached.
To complement the database searches, a citation
search was conducted. To the best of our knowledge,
the methods under study were ﬁrst applied to the ﬁeld
of vaccine safety by the Vaccine Safety Datalink
(VSD). Two key VSD papers that describe the testing
and implementation of rapid cycle analysis using rou-
tinely collected health data were selected to perform a
citation search.9,13
The same search strategy was used in the Web of
Science Core Collection to cover meetings and confer-
ences, restricting the search to meeting abstracts or
proceedings papers. Also, the Annual Conference on
Vaccine Research and the Vaccine and ISV Congress
abstract book and programme, respectively, were analysed
(Supporting Information Appendix B). The Brighton
Collaboration newsletter was also searched as a potential
source of relevant new studies or contacts.14
A second stage of the review included contacting
experts in vaccine safety, as follows:
• Specialists in vaccine safety (from the Global Advi-
sory Committee on Vaccine Safety (GACVS),15
Brighton Collaboration16 and Accelerated Devel-
opment of Vaccine beneﬁt–risk collaboration in
Europe (ADVANCE) 17) were asked if they were
aware of work being conducted in the area and
fulﬁlling our inclusion criteria.
• Authors with known work using routinely collected
data and the potential to have implemented/conducted
eligible studies were contacted (Medicines and
Healthcare products Regulatory Agency (MHRA),18
VSD19 and Statens Serum Institute20). Further con-
tacts were also asked for at this stage.
• Finally, authors with a previous published work but
incomplete information, and those suggested by
other experts, were contacted to ask for further
information to characterize the methods.
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An online questionnaire was used to capture infor-
mation on studies conducted (Supporting Information
Appendix C). When other sources of information
(e.g. reports) were available and shared by the con-
tacts these were used. Expert contacts took place
from February to March 2015.
The information identiﬁed was extracted using a
standardized extraction form. Data extracted included
timeline, country/institutions where the study was con-
ducted, vaccines studied, study population, outcomes
assessed and their method of ascertainment, methods
used to perform the analyses, frequency of assessment,
confounding, data-accrual lag (i.e. delays in the data
available to perform surveillance, which may affect
the results), assessment of the validity of the outcomes
of interest (e.g. chart review) and main results. A de-
scriptive summary of country/institution, vaccines,
outcomes studied, confounding and data-accrual lag
handling was drawn up.
RESULTS
A total of 29 reports were included for data extrac-
tion (including information provided by expert
contacts),9,13,21–45 representing 31 studies/systems
(Figure 1). A brief description of the studies/systems in-
cluded by country, methods used and adjustment for
confounding strategies is given in Table 1. A detailed
characterization of the studies is provided in Supporting
Information Appendix D.
Near real-time vaccine safety surveillance using
EHRs was ﬁrst reported by Davis et al. in 2005, when
a retrospective study assessing the feasibility of
implementing such methods was published. Since this
time, we identiﬁed a further 13 studies conducted
by the VSD and 17 other studies in three countries
(Figure 2). The ﬁrst study conducted outside the
VSD was conducted in New Zealand and published
in 2007. The report from the last study included
was published online in 2015. Four studies (all in
the USA) were conducted completely or partially
in a retrospective manner, to test the feasibility of
implementing this kind of system (Table 1). Two
of these studies attempted to replicate known sig-
nals (rotavirus vaccine and intussusception and
acellular diphtheria-tetanus-pertussis (DTaP)/whole
cell diphtheria-tetanus-pertussis vaccine and febrile
seizures). Of the prospective studies, most were
conducted in the USA (n=20), with studies also
conducted in the UK (n=6), and Taiwan and
New Zealand (n=1 for each). The prospective
studies looked mainly at inﬂuenza vaccines (n=16), es-
pecially the 2009 H1N1 pandemic inﬂuenza vaccine
(n=7). Rotavirus (n=5), DTaP-based (n=3) and human
papillomavirus vaccines (n=3) also received attention.
The outcomes studied were most often neurological
(58.5%). Looking at speciﬁc outcomes, Guillain-Barré
syndrome (GBS) (11.9% of studied known outcomes),
meningitis/encephalitis/myelitis (11.9%) and seizures
(10.8%) were the most often included. Outcome ascer-
tainment for the near real-time analysis was, in most
cases, based on automated data (with no a priori con-
ﬁrmation of the diagnosis). In these cases, chart review
and conﬁrmation were used whenever a potential AE
was signalled. Only two studies performed this kind
of conﬁrmation for the near real-time analysis,21,35
and one compared the analysis considering the chart-
reviewed and non-reviewed outcome for GBS.33 From
the outcomes studied, 11 signals were identiﬁed, but
only three conﬁrmed (measles-mumps-rubella-vari-
cella combination vaccine and febrile seizures,27
2010–2011 trivalent inactivated inﬂuenza vaccine
and febrile seizures,37 and monovalent rotavirus vac-
cine and intussusception41).
Table 2 summarizes the methods used by the stud-
ies included in this review. These can be broadly di-
vided into continuous sequential testing, which
allows examination of the data as often as desired
(n=25),9,13,22–34,37,38,40–43,45 group sequential testing
(n=4)35,36,38,39 and statistical process control (SPC;
n=3).21,44 The choice of the group of methods has
been determined by the frequency of updates to the
EHR data used (Table 2).
When considering speciﬁc versions of the tests
available, the choice has been guided by the increasing
availability of new methods and knowledge of these
methods over time, as shown in Figure 2, as well as
the frequency of AE studied. In VSD, the sequential
probability ratio test (SPRT) was ﬁrst applied9 being
subsequently replaced by its maximized version
(MaxSPRT) with the advantage of not having to spec-
ify a single alternative hypothesis.13 The use of
MaxSPRT and its variations also evolved over time.
While in the beginning the Poisson and binomial ver-
sions were simultaneously used for the same out-
come,13 from 2010, a targeted selection of the test
version and its extensions, based on the strengths of
each method (Table 2) and the characteristics of the
outcome under study, was preferred.24,33,34,42,43 In
particular, Poisson-based MaxSPRT (PMaxSPRT)
has been used when less than 50 events were antici-
pated and the conditional version when the ratio of ob-
served historical events to upper limit was ≤2.5.
Outside VSD, a pattern in the use of continuous sequen-
tial methods was less clear. Overall, these tests were the
most often employed—PMaxSPRT (45.7%),10,50
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followed by the binomial (BMaxSPRT—23.9%)10,50
and conditional (10.9%) versions.51
More recently, four studies used group sequential
testing. Two of these used an alpha-spending ap-
proach,38,39 (a function controlling how much of the
alpha will be ‘spent’ every time a new analysis is
run52), one the Updating Sequential Probability Ratio
Test53 and other the Abt’s modiﬁcation of SPRT.54
An alpha-spending approach was thus preferred over
the two other tests employed in a group sequential
way. Both the Pocock-type and O’Brien–Fleming-type
functions have been used.12,55 The remaining methods
did not follow a clear evolution and include use of
SPC56 at different times by two non-USA institutions
(New Zealand Ministry of Health, Health Protection
Scotland).21,44
Thirty-seven of 49 analyses (75.5%) mentioned con-
trol for confounding. Strategies chosen were often
design-based and included (alone or in combination)
the following: (i) using a self-controlled design, which
automatically addresses time-invariant confounders;
(ii) matching baseline confounders, through a concur-
rent comparator design; (iii) adjusting the expected
rate obtained from a historical comparison group
based on the confounders’ distribution in the study
cohort (iv) stratifying the results according to relevant
confounder categories. Analyses adjusting for poten-
tial confounders used mainly an expected rate adjusted
Figure 1. Flowchart of included studies. Studies were excluded for (i) not considering vaccines (nonvaccine), (ii) not analysing the safety of a vaccine (not
safety), (iii) considering safety issues but not applying the methods of interest (other safety), (iv) only developing new methods (methods only) and (v) having
no abstract available (not available)
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for potential confounders (51.4% of those adjusting),
stratiﬁcation (16.2%) or a combination of a self-
controlled design and stratiﬁcation (13.5%). The
choice of approaches also depended on the analytical
method selected. For group sequential methods and
SPC, strategies to deal with confounders were even
more limited. When employing group sequential
methods, only expected rate calculations based on
the confounders’ distribution and stratiﬁcation were
considered. For SPC, only stratiﬁcation was used. Po-
tential confounders considered include age, sex, geo-
graphic site, concomitant vaccine administration,
season and trend (Table 1).
Some of the prospective studies considered data-
accrual lags in their analysis. Most often, the analysis
was delayed by some weeks (n=7). Others adjusted
for partially elapsed risk intervals and delays in the ar-
rival of inpatient data (n=3).46 For studies using spon-
taneous report for the observed number of events (and
EHR for the expected number of events), sensitivity
analyses with several degrees of underreporting were
conducted (n=4).28,31,40 Updates to the previous
datasets already analysed were not considered a spe-
ciﬁc strategy to adjust for data-accrual lags as they
would not reduce the time to signal. The majority of
studies did not mention ways or did not adjust for
data-accrual lags (n=11).
DISCUSSION
Our comprehensive systematic review has identiﬁed
an increasing number of studies and systems
implementing NRTVSS. All the studies identiﬁed
were performed in high-income countries/regions with
most in the USA. This might reﬂect limited capacity in
many settings to provide registry data in a timely fash-
ion and the infra-structure required to set up the
system.
A clear effort was put into using these methods to
assess pandemic inﬂuenza vaccine safety. This vaccine
Figure 2. Studies included in the review, ordered by the year of publication. Continuous sequential test are underlined with single line, group sequential with
bold line, and statistical process control with dashed line. Grey background indicates non-published studies. *Results with previous published results.
maxSPRT – Maximized Sequential Probability Ratio Test, P – Poisson version (†use of the conditional version), B – binomial version (‡use of self-controlled
case-series or extensions of the test). DMSS – Defense Medical Surveillance System, DTaP – acellular diphtheria-tetanus-pertussis vaccine, DTwP – whole
cell diphtheria-tetanus-pertussis vaccine, GBMV – Group-B Meningococcal Vaccine, HPS – Health Protection Scotland, HPV2 – bivalent human papillomavirus
vaccine, HPV4 – quadrivalent human papillomavirus vaccine, IHS – (US) Indian Health Service, IPV – inactivated poliovirus vaccine, MCV –meningococcal
conjugate vaccine, MHRA – Medicines and Healthcare products Regulatory Agency, MMRV – Measles-Mumps-Rubella-Varicella combination vaccine,
PCV13 – 13-valent pneumococcal conjugate vaccine, PRISM – Post-Licensure Rapid Immunization Safety Monitoring, RRV – Rhesus-Rotavirus vaccine,
RV5 – pentavalent rotavirus vaccine, VA – Veteran’s Affaires, VSD – Vaccine Safety Datalink
near real-time vaccine safety surveillance 231
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is a good example of the importance of post-licensure
surveillance due to potential safety concerns.32 Menin-
gococcal group B vaccine in New Zealand21 repre-
sents a similar situation, where NRTVSS, along with
enhanced passive surveillance and other active
methods, was implemented after the vaccine was ap-
proved without phase III trials. Other situations where
these methods have been particularly useful include
vaccines/AE of concern due to experiences with
previous versions of the vaccine—for example,
rotavirus/intussusception25 and inﬂuenza/GBS.32 For
previously suspected AE, the set of methods here
reviewed has the advantage of informing in a timely
manner the existence of a safety concern or reassuring
regulatory authorities and the public about vaccine
safety.
In this review, we have identiﬁed different methods
to perform NRTVSS using EHR and the way these
have been applied, both by VSD and by other institu-
tions. All the methods identiﬁed are derived from
Wald’s sequential test.50,59,60 When choosing a partic-
ular method, it is important to be aware of its proper-
ties. Properties of the continuous and group
sequential methods have been studied in the context
of drug safety.12 Group sequential methods were
deemed to be more appropriate when data updates
are less frequent,12 but more recent work comparing
these methods has found that for any group sequential
design, there is a better continuous method and recom-
mended that the data are looked at as frequently as
possible.58 After selecting the methodological ap-
proach, it is necessary to choose the speciﬁc test to em-
ploy. For example, using the PMaxSPRT and
BMaxSPRT simultaneously might be a more robust
approach owing to complementary strengths. How-
ever, as previously suggested, BMaxSPRT might fail
to identify a signal when investigating very rare
events. Hence, an alternative is to use PMaxSPRT
when less than 50 events are anticipated and the condi-
tional version when the ratio of observed historical
events to upper limit is ≤2.5. The use of a targeted
approach has been considered in VSD’s more recent
work.24,33,34,42,43
On the other hand, the properties of SPC-based
methods applied to vaccine safety have not been ex-
tensively studied. Both Kulldorff et al.50 and Musonda
et al.61 have argued that SPC-based methods such as
cumulative sum are not appropriate to perform surveil-
lance for newly introduced products as the aim is to
detect a safety problem that is already present and
not a sudden change. These authors defend the use of
such methods in the context of surveillance for
batch-related problems (problems arising at the timeTa
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of manufacture rather than related to the product
itself). However, we should consider that at the time
of introduction, if there is a safety problem with that
speciﬁc vaccine and an appropriate comparison group
is used, a sudden change would be observable as well.
Given its ease of implantation, SPC is attractive, but
recommendations on the use of SPC are deferred until
further research on their properties is available.
Control for potential confounders has been limited
in both the strategies employed and factors adjusted
for. This observation is in agreement with Nelson
et al.,12 who have argued for better methods for con-
founder adjustment, in particular at the analysis stage.
Recent work has been performed in this area, adapting
group sequential methods with regression adjustment
and comparing this to existing approaches.62,63 To
the best of our knowledge, these promising approaches
are still at the development stage and have not yet
been applied to new studies. As pointed out by
Yih,11 it might not be possible to adjust for all possi-
ble confounders in this setting, which can lead to
spurious signals. However, it should be noted that,
as a near real-time analysis, aimed at quickly
identifying/strengthening signals, priority is given
to rapid results. As such, confounding adjustment is
not deemed as critical—more complete analyses
can be performed at conﬁrmatory stages.11 These
might include adjusting for additional confounders
or a more detailed adjustment (e.g. using ﬁner cate-
gorization of a variable) to avoid residual confound-
ing. The speciﬁc confounders to adjust for should be
decided on the basis of the vaccine, outcome and age
groups studied. In addition to those factors consid-
ered by studies, adjustments for day-of-the-week
effects or co-morbidities might be required.11 Never-
theless, 12 studies13,24–27,29,30,35,36 did not refer to
potential confounding in at least one of the analyses
reported in their published texts.
Best practice using EHR apply equally to NRTVSS
as to any study using these kind of data. For example,
Lanes et al. provide an approach to identify outcomes
in healthcare databases.64 One of the aspects to consider
while doing so is misclassiﬁcation. In some occasions,
manual review of individual medical records can be
used, particularly if a signal is found. In this review,
only two studies21,35 performed this conﬁrmation before
running the NRTVSS analysis, as doing so might delay
the surveillance process. Alternatively, multiple algo-
rithms might be developed, providing a trade-off be-
tween sensitivity and positive predictive values (PPV).
In the NRTVSS, an algorithm with higher sensitivity
and moderate PPV is generally considered to be timelier
than algorithms with moderate sensitivity algorithm and
high PPV. This should be considered for the speciﬁc
outcome under study, its seriousness and the data
available.65 Misclassiﬁcation of the exposure might
also be problematic. A possible approach is to restrict
the analysis to vaccinated individuals, avoiding poten-
tial biases.11
A key aspect to consider while using these methods is
the availability of timely data. ‘Real-time’ analyses are
difﬁcult to achieve, and thus, the expression ‘near real-
time’ is preferred. In fact, delays can occur at various
stages, including delays in diagnosis (e.g. for conditions
with more insidious onset), recording (e.g. retrospective
recording of vaccination administration or diagnosis),
receiving the data for analysis (due to either incomplete
data accrual or partially accrued risk windows) and
reporting. The timeliness of data should thus be con-
sidered. Some studies have delayed the analysis for
some weeks.13,23,25,27,41–43 While this approach gives
time for data to accrue, it will not reduce the time to
signal. The use of group sequential methods with less
frequent testing portrays a similar situation where
more time has been given for data to accrue.35,38,39
Nevertheless, for events occurring closer to the time
of testing, data-accrual lags may still be problematic.
Finally, adjustments for partially elapsed risk interval
and delays in the arrival of inpatient data have been
proposed (through the expected number of events)46
or integrated in the critical limits calculation36. These
can decrease the time to signal, based on previously
observed data-accrual patterns. They have been ap-
plied in a few, inﬂuenza vaccine, studies. Inﬂuenza
vaccines pose particular challenges when using de-
layed data as failure to detect a signal before the
season ends will impede adequate action. Strategies
proposed so far do not speciﬁcally address delays
between illness onset and diagnosis.
Only three of the 11 outcomes identiﬁed in the pro-
spective studies were conﬁrmed as true signals. In ad-
dition to issues already raised (confounding factors
that have not been considered, misclassiﬁcation of
the outcome), unconﬁrmed signals were due to (i)
changes in the true incidence or coding practices; (ii)
inappropriate comparison groups; (iii) uncertainty in
background rates; and (iv) type I errors.11,33 For type
I errors, additional strategies to reduce the false dis-
covery rate are available at the planning stage: these
include delaying the ﬁrst test,66 requiring a minimum
number of events to occur before rejecting the null hy-
pothesis67 or, in the case of group sequential tests,
selecting an O’Brien–Fleming threshold. The latter
spends less alpha in earlier tests and was used by
Nelson et al.38 During the surveillance period, it is im-
portant to update the critical limits as data arrive, as the
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observed data might differ from those planned.66 As in
the case of outcome identiﬁcation, these consider-
ations should be balanced against the importance of
detecting signals in a timely manner. Even after care-
ful consideration of all these aspects before and during
surveillance, possible spurious signals may still arise.
This emphasizes the need for a predetermined plan of
action for signal reﬁnement if a signal is found.11
The plan should include a careful decision on the data
source to use to test the hypothesis in subsequent anal-
yses if needed, owing to potential biases with the use
of the same data to identify and test the signals.
NRTVSS is thus not a stand-alone method but part
of the signal detection and evaluation process.
This review aimed at capturing studies and systems
worldwide using EHR to perform NRTVSS. Our rig-
orous search strategy and further contacts with many
experts on vaccine safety from different countries
and institutions (with a satisfactory response rate,
70.6%) should have minimized the risk of missing sys-
tems currently in use. However, we cannot exclude the
existence of similar systems elsewhere. Furthermore,
some information was missing from the studies in-
cluded, which we have tried to reduce by contacting
the authors. The missing information most often re-
lated to confounding control strategies and the data-
accrual lag adjustment employed. This might reﬂect
the limited options to address these issues, especially
for the earlier studies.
Countries considering introduction of these methods
should beneﬁt from the work developed so far and
from strategies under development. There should be
a cautious reﬂection on the availability of timely data
and their characteristics (including discussion with
the data providers), the vaccine(s) and outcome(s) to
be studied and the infra-structure needed in case a sig-
nal is detected. Future directions for research might
include further development and application of strate-
gies for adjustment for confounding and data-accrual
lag, as well as consideration of other methods not yet
applied to observational settings but in use in clinical
trials, for example, Bayesian approaches to group se-
quential tests.68 Bayesian methods can incorporate
previous information (such as the data generated by
pre-licensure studies) and potentially provide a more
ﬂexible approach.
In conclusion, NRTVSS using EHR to assess the
safety of newly introduced vaccines is being increas-
ingly used in the USA, with limited introduction in a
few other countries. These methods ensure timely de-
tection of safety signals. New methods have been inte-
grated over time, but strategies to account for potential
confounders and data-accrual lags have received less
attention. As new vaccines are expected to be intro-
duced and the public questions vaccine safety, the
demand for strong post-licensure surveillance systems
will increase.
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